Unavailable · 09.11.2026
Supply shortage Belgium: Amoxiclav Sandoz 2 000 mg - 200 mg inf. sol. (pwdr.) i.v. vial 10 (2000 mg - 200 mg) – Unavailable, 09.11.2026 · ENR FAMHP-ID 6ae07d5bba661719ff667819; BE271214
Affected country: Belgium · Reported period: 23.11.2026 – 29.01.2027 · Active ingredient: Clavulanic Acid,Amoxicillin
Active ingredients
Notice context
A supply shortage has been recorded for Amoxiclav Sandoz 2 000 mg - 200 mg inf. sol. (pwdr.) i.v. vial 10 (2000 mg - 200 mg) in Belgium. The stated reason is “Manufacturing delay”. The notice concerns the active ingredient Clavulanic Acid,Amoxicillin and is not identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Belgium. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Amoxiclav Sandoz 2 000 mg - 200 mg inf. sol. (pwdr.) i.v. vial 10 (2000 mg - 200 mg) is a supply signal concerning Clavulanic Acid,Amoxicillin in Belgium. The published reason “Manufacturing delay” determines which data should be verified first.
For manufacturing or capacity constraints, the focus is on credible restart dates, available batches, qualified sources and the coverage of existing stock.
Once a lawful sourcing route is confirmed and buffer stock is required, our pharma warehouse in Cheb page explains receipt, stock control and picking.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess restart timing, available batches, qualified sources and a lawful bridging stock separately.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For manufacturing shortages, an agreed restart stock for Amoxiclav Sandoz 2 000 mg - 200 mg inf. sol. (pwdr.) i.v. vial 10 (2000 mg - 200 mg) can be received and distributed under control after release.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using CNK 2215986, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 23.11.2026 to 29.01.2027 with the primary source and potential suppliers.
- Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Amoxiclav Sandoz 2 000 mg - 200 mg inf. sol. (pwdr.) i.v. vial 10 (2000 mg - 200 mg):